According to the research report titled ‘Global NASH Market - Analysis By Drug Type, Sales Chanel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)’, available with Market Study Report LLC, global NASH market was valued at USD 3369.12 million in 2020 and is likely to expand significantly during 2021-2026.
 

Increased pervasiveness of NASH and rising demand for relevant therapeutics are some of the key factors driving the growth of global NASH market. Technological advancements have allowed for development of special MRI solutions which help in determining the fat percentage as well as the scarring present in the body, which in turn is also stimulating the industry outlook.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3578562/
 

These developments could also help in eliminating the need for a liver biopsy. For those unaware, a patient will go through a liver biopsy if NASH is detected. It is usually the first-line of approach during which a needle is used to remove a small tissue piece from the liver. This is then examined using a microscope, further allowing physicians to determine if any inflammation of scarring of the liver.
 

The outbreak of COVID-19 has severely impacted the growth of global NASH market, especially due to halt in research & development efforts and inability to raise the required funds. The disease outbreak has also affected the operations of EMA, FDA and other health authorities, putting a delay to clinical development efforts and approval of product candidates.
 

Citing the sales channel, the report cites that the retail pharmacy segment is likely to accrue substantial revenues for global NASH market in the upcoming years. Various biopharmaceutical manufacturers are known to sell drugs to few retail pharmacies in order to maintain a competitive advantage in this business space, which in turn is favoring the overall market scenario.
 

Regionally speaking, North America presently holds the largest market share and is likely to showcase similar growth patterns in the forthcoming years.
 

The competitive landscape of global NASH market is defined by companies such as Gilead Sciences Inc., Horizon Therapeutics plc, AstraZeneca plc, GENFIT S.A., Intercept Pharmaceuticals Inc., Zydus Cadila (Cadila Healthcare Limited), 3M Co., and Novartis AG among others.